The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring

The emerging field of liquid biopsy stands at the forefront of novel diagnostic strategies for cancer and other diseases. Liquid biopsy allows minimally invasive molecular characterization of cancers for diagnosis, patient stratification to therapy, and longitudinal monitoring. Liquid biopsy strategies include detection and monitoring of circulating tumor cells, cell-free DNA, and extracellular vesicles. In this review, we address the current understanding and the role of existing liquid-biopsy-based modalities in cancer diagnostics and monitoring. We specifically focus on the technical and clinical challenges associated with liquid biopsy and biomarker development being addressed by the Liquid Biopsy Consortium, established through the National Cancer Institute. The Liquid Biopsy Consortium has developed new methods/assays and validated existing methods/technologies to capture and characterize tumor-derived circulating cargo, as well as addressed existing challenges and provided recommendations for advancing biomarker assays.

Type

Journal article

Citation

Batool, S. M., Yekula, A., Khanna, P., Hsia, T., Gamblin, A. S., Ekanayake, E., Escobedo, A. K., You, D. G., Castro, C. M., Im, H., Kilic, T., Garlin, M. A., Skog, J., Dinulescu, D. M., Dudley, J., Agrawal, N., Cheng, J., Abtin, F., Aberle, D. R., … Balaj, L. (2023). The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring. Cell Reports Medicine, 4(10), 101198. https://doi.org/10.1016/j.xcrm.2023.101198

Published Version

https://doi.org/10.1016/j.xcrm.2023.101198

Rights

Except where otherwise noted, this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND) license. Permission to reuse, publish, or reproduce the work beyond the terms of the license or beyond the bounds of fair use or other exemptions to copyright law must be obtained from the copyright holder.